Caxton Associates LLP Denali Therapeutics Inc. Transaction History
Caxton Associates LLP
- $3.94 Trillion
- Q2 2025
A detailed history of Caxton Associates LLP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 14,229 shares of DNLI stock, worth $219,411. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,229Holding current value
$219,411% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
247Shares Held
135MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$203 Million0.01% of portfolio
-
Baillie Gifford & CO12MShares$184 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$182 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$101 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$96.6 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.07B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...